ARS Pharmaceuticals, Inc. - 8-K Filing
On June 24, 2026, ARS Pharmaceuticals held its annual stockholder meeting where four proposals were voted on. Stockholders elected three Class III directors with votes in favor ranging from 51.5 million to 45.1 million; ratified Ernst & Young LLP as the independent auditor with 79.5 million votes for; approved executive compensation with 57.3 million votes for and against at 8.1 million; and selected annual frequency for future advisory votes on executive pay, receiving 52.1 million votes in favor. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $SPRY